- 询价
- 晶抗生物
- JK260375
- 上海
- 2025年07月12日
- 科研试验
- Rabbit
- Human,Mouse,Rat,Chicken,Dog,Cow,Rabbit,Sheep
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 供应商：
上海晶抗生物工程有限公司
- 库存：
大量
- 克隆性：
多克隆
- 保质期：
1年
- 抗体英文名：
Anti-SLC9A3 antibody
- 宿主：
Rabbit
- 适应物种：
Human,Mouse,Rat,Chicken,Dog,Cow,Rabbit,Sheep
- 应用范围：
科研试验
- 保存条件：
-20°C
- 规格：
25 μl/100 μl/200 μl
Anti-SLC9A3 antibody
Cat. No. JK260375
Package 25 μl/100 μl/200 μl
Storage -20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
Product overview
Description Anti-SLC9A3 rabbit polyclonal antibody
Applications ELISA, IHC
Immunogen Synthetic peptide of human SLC9A3
Reactivity Human, Mouse, Rat
Content 0.4 mg/ml
Host species Rabbit
Ig class Immunogen-specific rabbit IgG
Purification Antigen affinity purification
Target information
Symbol SLC9A3
Full name solute carrier family 9, subfamily A (NHE3, cation proton antiporter 3), member 3
Synonyms NHE3
Swissprot P48764
Target Background
Sodium–hydrogen antiporter 3 also known as sodium–hydrogen exchanger 3 (NHE3) or solute carrier family 9 member 3 (SLC9A3) is a protein that in humans is encoded by the SLC9A3 gene. SLC9A3 is a sodium–hydrogen antiporter. It is found in the nephron of the kidney and in the apical membrane of enterocytes of the intestine. It is primarily responsible for maintaining the balance of sodium. Binds SLC9A3R1 and SLC9A3R2. Interacts with CHP1, CHP2 and SHANK2. Interacts with PDZD3 and interactions decrease in response to elevated calcium ion levels.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验a simple ELISA method to detect human anti-antibody response.
Purification Of Anti Peptide Antibody
antibody that could contribute to staining background. The proportion in each pool varies with the peptide immunogen. The quality of the anti-peptide serum seems to increase with multiple boosts - the first bleed may be feeble.
Anticardiolipin Antibody and Anti-beta 2 Glycoprotein I Antibody Assays
standard” laboratory test to diagnose or classify a patient as having APS. This chapter discusses the clinical and laboratory theoretical and technical aspects of aCL and anti-β2GPI antibody assays.
